/wp-content/themes/enfold/

The list has been updated through December 2017.

It's been a tumultuous four years for Olivier Brandicourt at Sanofi, marked by restructuring, cost cuts, an asset swap and two rare disease buyouts. What happens over the next four years is anybody's guess, but the company's deciding now who'll be at the helm, a spokeswoman said.